Cargando…
Rezvilutamide for metastatic castration-sensitive prostate cancer: CHART trial
Autor principal: | Singh, Kirti |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10249535/ https://www.ncbi.nlm.nih.gov/pubmed/37304989 http://dx.doi.org/10.4103/iju.iju_336_22 |
Ejemplares similares
-
Triple therapy for metastatic castration sensitive prostate cancer: PEACE-1 trial
por: Singh, Kirti
Publicado: (2022) -
LATITUDE: A landmark trial for high-risk metastatic castration-sensitive prostate cancer: Final overall survival analysis
por: Kumar, Gautam
Publicado: (2020) -
Benefit of cabazitaxel in previously treated metastatic castration-resistant prostate cancer; CARD trial
por: Mishra, Ankit
Publicado: (2020) -
VISION trial: (177)Lu-PSMA-617 for progressive metastatic castration-resistant prostate cancer
por: Rohith, Gorrepati
Publicado: (2021) -
Apalutamide: A novel therapy for non metastatic castration-resistant carcinoma prostate
por: Jayasimha, Sudhindra
Publicado: (2018)